{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:04:44Z","timestamp":1791644684622,"version":"4.3.4"},"reference-count":22,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,10,15]]},"published-print":{"date-parts":[[2025,1]]},"DOI":"10.2967\/jnumed.124.268167","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T16:00:20Z","timestamp":1731600020000},"page":"47-53","source":"Crossref","is-referenced-by-count":23,"title":["PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received<sup>177<\/sup>Lu-PSMA-617: Importance of<sup>18<\/sup>F-FDG\u2013Avid Discordant Findings"],"prefix":"10.2967","volume":"66","author":[{"given":"Ridvan Arda","family":"Demirci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Ghodsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaz","family":"Behnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Yezefski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E.","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Iravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"2025010313152047000_66.1.47.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025010313152047000_66.1.47.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"issue":"5","key":"2025010313152047000_66.1.47.3","first-page":"14N","article-title":"Updates to appropriate use criteria for PSMA PET","volume":"63","author":"Hope","year":"2022","journal-title":"J Nucl Med."},{"key":"2025010313152047000_66.1.47.4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025010313152047000_66.1.47.5","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol."},{"key":"2025010313152047000_66.1.47.6","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s00259-020-05160-8","article-title":"Prognostic implications of dual tracer PET\/CT: PSMA ligand and [18F]FDG PET\/CT in patients undergoing [177Lu]PSMA radioligand therapy","volume":"48","author":"Michalski","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025010313152047000_66.1.47.7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12149-023-01874-5","article-title":"Comparison of PET\/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy","volume":"38","author":"Michalski","year":"2024","journal-title":"Ann Nucl Med."},{"key":"2025010313152047000_66.1.47.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265346"},{"key":"2025010313152047000_66.1.47.9","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/j.clgc.2021.01.008","article-title":"Molecular imaging of neuroendocrine differentiation of prostate cancer: a case series","volume":"19","author":"Iravani","year":"2021","journal-title":"Clin Genitourin Cancer."},{"key":"2025010313152047000_66.1.47.10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamaoncol.2017.3588","article-title":"Positron emission tomography\/computed tomography-based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer","volume":"4","author":"Fox","year":"2018","journal-title":"JAMA Oncol."},{"key":"2025010313152047000_66.1.47.11","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","article-title":"LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC) [abstract]","volume":"41","author":"Sandhu","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025010313152047000_66.1.47.12","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","article-title":"PRINCE: phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC) [abstract]","volume":"40","author":"Sandhu","year":"2022","journal-title":"J Clin Oncol."},{"key":"2025010313152047000_66.1.47.13","doi-asserted-by":"crossref","first-page":"TPS278","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS278","article-title":"LuCAB: a phase I\/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) [abstract]","volume":"41","author":"Kostos","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025010313152047000_66.1.47.14","doi-asserted-by":"crossref","first-page":"1059122","DOI":"10.3389\/fmed.2022.1059122","article-title":"AlphaBet: combination of radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)","volume":"9","author":"Kostos","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"2025010313152047000_66.1.47.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00274-6"},{"key":"2025010313152047000_66.1.47.16","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s00259-023-06281-6","article-title":"SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T","volume":"50","author":"Hartrampf","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025010313152047000_66.1.47.17","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025010313152047000_66.1.47.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.231431"},{"key":"2025010313152047000_66.1.47.19","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","article-title":"[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a VISION substudy [abstract]","volume":"40","author":"Kuo","year":"2022","journal-title":"J Clin Oncol."},{"key":"2025010313152047000_66.1.47.20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41391-019-0174-x","article-title":"Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies","volume":"23","author":"Iravani","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2025010313152047000_66.1.47.21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.euo.2018.11.007","article-title":"Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy","volume":"2","author":"Thang","year":"2019","journal-title":"Eur Urol Oncol."},{"key":"2025010313152047000_66.1.47.22","doi-asserted-by":"crossref","first-page":"TPS211","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS211","article-title":"PSMAfore: a phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-na\u00efve patients with metastatic castration-resistant prostate cancer [abstract]","volume":"40","author":"Sartor","year":"2022","journal-title":"J Clin Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T21:16:37Z","timestamp":1735938997000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,3]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.2967\/jnumed.124.268167"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268167","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]}}}